IL227414A - Composition comprising an angiotensin receptor type 1 blocker or pharmaceutical salt thereof and a chemokine receptor 2 inhibitor or pharmaceutical salt thereof and uses thereof in the preparation of medicaments - Google Patents

Composition comprising an angiotensin receptor type 1 blocker or pharmaceutical salt thereof and a chemokine receptor 2 inhibitor or pharmaceutical salt thereof and uses thereof in the preparation of medicaments

Info

Publication number
IL227414A
IL227414A IL227414A IL22741413A IL227414A IL 227414 A IL227414 A IL 227414A IL 227414 A IL227414 A IL 227414A IL 22741413 A IL22741413 A IL 22741413A IL 227414 A IL227414 A IL 227414A
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
acceptable salt
ccr2
blocker
inhibitor
Prior art date
Application number
IL227414A
Other languages
English (en)
Hebrew (he)
Other versions
IL227414A0 (en
Original Assignee
Dimerix Bioscience Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46506697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL227414(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2011900060A external-priority patent/AU2011900060A0/en
Application filed by Dimerix Bioscience Pty Ltd filed Critical Dimerix Bioscience Pty Ltd
Publication of IL227414A0 publication Critical patent/IL227414A0/en
Publication of IL227414A publication Critical patent/IL227414A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL227414A 2011-01-11 2013-07-10 Composition comprising an angiotensin receptor type 1 blocker or pharmaceutical salt thereof and a chemokine receptor 2 inhibitor or pharmaceutical salt thereof and uses thereof in the preparation of medicaments IL227414A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2011900060A AU2011900060A0 (en) 2011-01-11 Combination Therapy
US201161432896P 2011-01-14 2011-01-14
US201161547951P 2011-10-17 2011-10-17
AU2011904279A AU2011904279A0 (en) 2011-10-17 Combination Therapy
PCT/AU2012/000014 WO2012094703A1 (en) 2011-01-11 2012-01-11 Combination therapy

Publications (2)

Publication Number Publication Date
IL227414A0 IL227414A0 (en) 2013-09-30
IL227414A true IL227414A (en) 2017-06-29

Family

ID=46506697

Family Applications (1)

Application Number Title Priority Date Filing Date
IL227414A IL227414A (en) 2011-01-11 2013-07-10 Composition comprising an angiotensin receptor type 1 blocker or pharmaceutical salt thereof and a chemokine receptor 2 inhibitor or pharmaceutical salt thereof and uses thereof in the preparation of medicaments

Country Status (9)

Country Link
US (6) US9314450B2 (https=)
EP (4) EP3586844A1 (https=)
JP (4) JP6087836B2 (https=)
CN (2) CN103476410B (https=)
AU (1) AU2012206945B2 (https=)
CA (1) CA2821985C (https=)
IL (1) IL227414A (https=)
WO (1) WO2012094703A1 (https=)
ZA (1) ZA201305897B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547366A4 (en) 2010-03-18 2013-08-07 Univ Colorado State Res Found SUPPRESSOR CELL HEMMER OBTAINED FROM MYELOID CELLS
EP2726108B1 (en) 2011-06-29 2018-01-10 The Trustees of Columbia University in the City of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
WO2014075096A1 (en) * 2012-11-09 2014-05-15 The Trustees Of Columbia University In The City Of New York Inhibitors of central nervous system vasoactive inhibitory peptide receptor 2
EP2962691A4 (en) * 2013-02-28 2016-08-31 Santen Pharmaceutical Co Ltd AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE POSTERIOR PART OF THE IL CONTAINING A TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS ACTIVE INGREDIENT
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
WO2014134621A2 (en) * 2013-03-01 2014-09-04 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
CN103193771B (zh) * 2013-03-29 2015-08-05 中国人民解放军军事医学科学院生物工程研究所 链状酰胺类ccr5受体抑制剂的药物新用途
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
MX2017000580A (es) * 2014-07-17 2017-09-01 Santen Pharmaceutical Co Ltd Agente profilactico o terapeutico para enfermedades del segmento posterior del ojo.
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
US20180360846A1 (en) * 2015-09-16 2018-12-20 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
MX2021014356A (es) * 2016-11-23 2022-11-24 Chemocentryx Inc Metodo para tratar glomeruloesclerosis segmentaria focal.
AU2018347361A1 (en) 2017-10-11 2020-04-30 Chemocentryx, Inc. Treatment of focal segmental glomerulosclerosis with CCR2 antagonists
CN108218789A (zh) * 2018-03-12 2018-06-29 钦州学院 碳13氘代甲基替米沙坦及其制备方法和用途
EP3807898A1 (en) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
IL287220B2 (en) * 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
CN114466653A (zh) * 2019-09-26 2022-05-10 戴麦里克斯生物科学有限公司 用于治疗疾病的方法和组合物
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
GB202006079D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
US20230165838A1 (en) * 2020-05-06 2023-06-01 Dimerix Bioscience Ltd. Treatment for acute respiratory distress syndrome
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
WO2022198264A1 (en) * 2021-03-23 2022-09-29 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd
IL320391A (en) * 2022-10-24 2025-06-01 Hadasit Med Res Service Modulators and uses thereof
TW202444344A (zh) * 2023-05-12 2024-11-16 澳大利亞商迪美力士生物科技有限公司 用於腎病之治療調配物
CN117054652B (zh) * 2023-08-04 2024-05-17 南京医科大学 一种用于辅助检测心肌肥厚的生物标志物及其应用
EP4686469A1 (en) * 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8 inhibitors for use in the treatment of diabetes-associated comorbidities

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
US5492904A (en) 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
JPH059116A (ja) 1991-07-01 1993-01-19 Sanwa Kagaku Kenkyusho Co Ltd ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤
WO1996040258A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
WO2000025134A1 (en) 1998-10-23 2000-05-04 Glaxo Group Limited Assays for ligands for nuclear receptors
CA2399080C (en) * 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
US6893827B1 (en) 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
US7262185B2 (en) * 2001-08-08 2007-08-28 Takeda Chemical Industries Ltd. Benzazepine derivative, process for producing the same, and use
DE10218785A1 (de) 2002-04-26 2003-11-13 Infineon Technologies Ag Halbleiterspeichereinrichtung und Betriebsverfahren für eine Halbleiterspeichereinrichtung
JP2004093527A (ja) 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
EP1481996A1 (en) 2003-05-30 2004-12-01 KRATON Polymers Research B.V. Process for making a coupled block copolymer composition
JP4734498B2 (ja) 2003-07-09 2011-07-27 ライフ テクノロジーズ コーポレイション タンパク質−タンパク質相互作用を解析する方法
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
WO2005050182A1 (en) 2003-11-19 2005-06-02 Dimerix Biosciences Pty Ltd Resonance energy transfer assay system for multi-component detection
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
JPWO2006028007A1 (ja) * 2004-09-06 2008-05-08 興和株式会社 糸球体疾患治療剤
GT200500246A (es) * 2004-09-09 2006-04-17 Combinacion de compuestos organicos
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
DK2080012T3 (da) 2006-11-10 2013-06-17 Dimerix Bioscience Pty Ltd Fremgangsmåder til analyse af testforbindelser på forbundne receptorer.
CN101535830B (zh) 2006-11-10 2013-07-17 皇家飞利浦电子股份有限公司 预防磁共振检查系统中的失超
CA2669917A1 (en) * 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
WO2008113095A1 (en) 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
MX2010003113A (es) * 2007-09-25 2010-04-01 Abbott Lab Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina.
US20110009482A1 (en) 2007-12-04 2011-01-13 Schering Corporation Methods of treating copd
CA2720547A1 (en) 2008-04-07 2009-10-15 Cardoz Ab New combination for use in the treatment of inflammatory disorders
EP2389178A4 (en) 2008-12-01 2012-06-06 Invasc Therapeutic Inc COMPOSITIONS CONTAINING INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND LIPOIC ACID COMPOUNDS, AND THEIR USE FOR THE TREATMENT OF RENIN-ANGIOTENSIN-ALDOSTERONE ASSOCIATED DISORDERS
US8537791B2 (en) 2009-01-20 2013-09-17 Lg Electronics Inc. Method and apparatus for channel access in contention-based communication system and station
WO2010108232A1 (en) * 2009-03-27 2010-09-30 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers

Also Published As

Publication number Publication date
US20160243127A1 (en) 2016-08-25
JP2018127498A (ja) 2018-08-16
US10525038B2 (en) 2020-01-07
EP3586844A1 (en) 2020-01-01
US9314450B2 (en) 2016-04-19
AU2012206945A1 (en) 2013-07-04
CN103476410A (zh) 2013-12-25
IL227414A0 (en) 2013-09-30
US20200046685A1 (en) 2020-02-13
JP6087836B2 (ja) 2017-03-01
CN103476410B (zh) 2020-02-21
US20220323418A1 (en) 2022-10-13
EP4711006A2 (en) 2026-03-18
US20130289084A1 (en) 2013-10-31
CA2821985A1 (en) 2012-07-19
AU2012206945B2 (en) 2015-02-19
JP2020122015A (ja) 2020-08-13
JP2017078085A (ja) 2017-04-27
EP2663304A4 (en) 2014-06-25
US20180000826A1 (en) 2018-01-04
WO2012094703A1 (en) 2012-07-19
CN107899012A (zh) 2018-04-13
EP2663304B1 (en) 2019-11-20
JP2014505049A (ja) 2014-02-27
CA2821985C (en) 2019-07-09
US10058555B2 (en) 2018-08-28
US11382896B2 (en) 2022-07-12
US12083102B2 (en) 2024-09-10
EP4215194A1 (en) 2023-07-26
ZA201305897B (en) 2014-04-30
EP4215194B1 (en) 2026-03-25
EP2663304A1 (en) 2013-11-20
US20240366570A1 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
US12083102B2 (en) Method for treating inflammatory disorders
JP5968927B2 (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
US20230364037A1 (en) Cancer therapeutic
US20220226293A1 (en) Treatments of angioedema
US20230381162A1 (en) Treatments of angioedema
CN117042763A (zh) 炎性疾病的治疗
WO2021222972A1 (en) Treatment for acute respiratory distress syndrome
HK1192712A (en) Combination therapy
HK1192712B (en) Combination therapy
ES2770785T3 (es) Terapia de combinación
CN107072977B (zh) Nep抑制剂药物组合及其应用
WO2021222971A1 (en) Treatment for virus induced acute respiratory distress syndrome
CN101361736A (zh) 一种沙坦化合物或其可药用盐和钙通道阻断剂或可药用盐的复方

Legal Events

Date Code Title Description
NP Permission for amending the patent specification granted (section 66, patents law 1967)
FF Patent granted
KB Patent renewed